These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32902291)

  • 1. RNA Interference Nanotherapeutics for Treatment of Glioblastoma Multiforme.
    Singh P; Singh A; Shah S; Vataliya J; Mittal A; Chitkara D
    Mol Pharm; 2020 Nov; 17(11):4040-4066. PubMed ID: 32902291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual bioluminescence and near-infrared fluorescence monitoring to evaluate spherical nucleic acid nanoconjugate activity in vivo.
    Sita TL; Kouri FM; Hurley LA; Merkel TJ; Chalastanis A; May JL; Ghelfi ST; Cole LE; Cayton TC; Barnaby SN; Sprangers AJ; Savalia N; James CD; Lee A; Mirkin CA; Stegh AH
    Proc Natl Acad Sci U S A; 2017 Apr; 114(16):4129-4134. PubMed ID: 28373576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
    Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
    Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functionalized nanogels carrying an anticancer microRNA for glioblastoma therapy.
    Shatsberg Z; Zhang X; Ofek P; Malhotra S; Krivitsky A; Scomparin A; Tiram G; Calderón M; Haag R; Satchi-Fainaro R
    J Control Release; 2016 Oct; 239():159-68. PubMed ID: 27569663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against Glioblastoma Multiforme.
    Janaki Ramaiah M; Divyapriya K; Kartik Kumar S; Rajesh YBRD
    Gene; 2020 Jan; 723():144126. PubMed ID: 31589963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted nanocomplex carrying siRNA against MALAT1 sensitizes glioblastoma to temozolomide.
    Kim SS; Harford JB; Moghe M; Rait A; Pirollo KF; Chang EH
    Nucleic Acids Res; 2018 Feb; 46(3):1424-1440. PubMed ID: 29202181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo.
    Sarli SL; Fakih HH; Kelly K; Devi G; Rembetsy-Brown JM; McEachern HR; Ferguson CM; Echeverria D; Lee J; Sousa J; Sleiman HF; Khvorova A; Watts JK
    Nucleic Acids Res; 2024 May; 52(9):4799-4817. PubMed ID: 38613388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma.
    Tommasini-Ghelfi S; Lee A; Mirkin CA; Stegh AH
    Methods Mol Biol; 2019; 1974():371-391. PubMed ID: 31099015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo delivery aspects of miRNA, shRNA and siRNA.
    Khatri N; Rathi M; Baradia D; Trehan S; Misra A
    Crit Rev Ther Drug Carrier Syst; 2012; 29(6):487-527. PubMed ID: 23176057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted electro-delivery of oligonucleotides for RNA interference: siRNA and antimiR.
    Chabot S; Teissié J; Golzio M
    Adv Drug Deliv Rev; 2015 Jan; 81():161-8. PubMed ID: 24819217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of oligonucleotide delivery.
    Takeshita F; Takahashi RU; Onodera J; Ochiya T
    Methods Mol Biol; 2012; 872():243-53. PubMed ID: 22700416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interfering cancer with polymeric siRNA nanomedicines.
    Tiram G; Scomparin A; Ofek P; Satchi-Fainaro R
    J Biomed Nanotechnol; 2014 Jan; 10(1):50-66. PubMed ID: 24724498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.
    Krichevsky AM; Uhlmann EJ
    Neurotherapeutics; 2019 Apr; 16(2):319-347. PubMed ID: 30644073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RNAi in clinical studies.
    Kubowicz P; Żelaszczyk D; Pękala E
    Curr Med Chem; 2013; 20(14):1801-16. PubMed ID: 23432579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted delivery of small noncoding RNA for glioblastoma.
    Yoo JY; Yeh M; Kaur B; Lee TJ
    Cancer Lett; 2021 Mar; 500():274-280. PubMed ID: 33176185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.
    Lozada-Delgado EL; Grafals-Ruiz N; Vivas-Mejía PE
    Life Sci; 2017 Nov; 188():26-36. PubMed ID: 28864225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma.
    Michiue H; Eguchi A; Scadeng M; Dowdy SF
    Cancer Biol Ther; 2009 Dec; 8(23):2306-13. PubMed ID: 19901546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RNA interference and cancer therapy.
    Wang Z; Rao DD; Senzer N; Nemunaitis J
    Pharm Res; 2011 Dec; 28(12):2983-95. PubMed ID: 22009588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.